The company reported Q2 2026 revenue of $2.5 million as CMS proposes raising TULSA procedure payments to $15,494.
Profound Medical Corp. maintained its 2026 revenue outlook of approximately $25 million following a CMS proposal to increase OPPS payments by 14.9% to $15,494 per TULSA procedure. The company reported Q2 2026 revenue of $2.5 million, including $1.6 million from recurring revenue and $871,000 from other sources.
Revenue recognition timing dominated discussions during the quarter, with management highlighting the breakdown of revenue streams. The proposed CMS payment increase could bolster future procedure volumes and revenue growth.
No immediate market reaction was disclosed in the earnings call summary.